Karyopharm Therapeutics
KPTI
129 hedge funds and large institutions have $340M invested in Karyopharm Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 30 reducing their positions, and 43 closing their positions.
101% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $515K
73% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 30
2% more capital invested
Capital invested by funds: $334M → $340M (+$5.77M)
0.65% less ownership
Funds ownership: 5.79% → 5.15% (-0.65%)
16% less funds holding
Funds holding: 154 → 129 (-25)
58% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.59M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.22M |
| 3 |
Barclays
London,
United Kingdom
|
+$5.93M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.28M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$13.1M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$12.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.77M |
| 4 |
CC
Commodore Capital
New York
|
-$6.58M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$6.55M |
KPTI Hedge Fund Activity: Q1 2023 in Review
129 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2023, worth a combined $340M — up 1.7% from $334M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of KPTI and 18 opened new positions — a net loss of 25 holders — while 30 trimmed existing stakes and 52 added.
The largest buyer was Vanguard Group, adding an estimated $7.59M. The largest seller was Armistice Capital, exiting entirely with an estimated $13.1M sold.
- 129 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2023, down from 154 in Q4 2022.
- Funds reported $340M of Karyopharm Therapeutics stock for Q1 2023, up 1.7% quarter-over-quarter.
- 18 funds opened new Karyopharm Therapeutics positions in Q1 2023 and 43 closed out, a net change of -25 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $7.59M added.
- The largest Karyopharm Therapeutics seller in Q1 2023 was Armistice Capital, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2023.